Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022889910> ?p ?o ?g. }
- W2022889910 endingPage "87" @default.
- W2022889910 startingPage "82" @default.
- W2022889910 abstract "ObjectiveTo evaluate the impact of aromatase inhibitors as adjuvant treatment in IVF cycles on intraovarian androgens and cycle outcome.DesignObservational, pilot study.SettingUniversity-affiliated IVF unit.Patient(s)One hundred forty-seven low responder patients with a previous canceled IVF cycle; 71 patients were treated with letrozole 2.5 mg plus a high-dose FSH/hMG-antagonist regimen, and 76 patients were similarly treated but letrozole was not employed.Intervention(s)In vitro fertilization treatment with an antagonist FSH/hMG protocol with or without letrozole was administered during the first 5 days of stimulation; hormones were evaluated in both serum and follicular fluid.Main Outcome Measure(s)Number of oocytes retrieved, fertilization rate, implantation rate, and pregnancy rate; androstenedione, T, E2, and P values in serum and follicular fluid.Result(s)Letrozole-treated patients showed significantly higher levels of follicular fluid T and androstenedione (80.3 vs. 43.8 pg/mL and 57.9 vs. 37.4 mg/mL, respectively). Similarly, these patients had a higher number of oocytes retrieved (6.1 vs. 4.3) and a higher implantation rate (25% vs. 9.4%) despite similar doses of FSH/hMG (3,627 vs. 3,804 IU).Conclusion(s)Adding 2.5 mg of letrozole to a high-dose FSH/hMG antagonist protocol increases intraovarian androstenedione and T concentration and improves IVF cycle outcome in poor responder patients. To evaluate the impact of aromatase inhibitors as adjuvant treatment in IVF cycles on intraovarian androgens and cycle outcome. Observational, pilot study. University-affiliated IVF unit. One hundred forty-seven low responder patients with a previous canceled IVF cycle; 71 patients were treated with letrozole 2.5 mg plus a high-dose FSH/hMG-antagonist regimen, and 76 patients were similarly treated but letrozole was not employed. In vitro fertilization treatment with an antagonist FSH/hMG protocol with or without letrozole was administered during the first 5 days of stimulation; hormones were evaluated in both serum and follicular fluid. Number of oocytes retrieved, fertilization rate, implantation rate, and pregnancy rate; androstenedione, T, E2, and P values in serum and follicular fluid. Letrozole-treated patients showed significantly higher levels of follicular fluid T and androstenedione (80.3 vs. 43.8 pg/mL and 57.9 vs. 37.4 mg/mL, respectively). Similarly, these patients had a higher number of oocytes retrieved (6.1 vs. 4.3) and a higher implantation rate (25% vs. 9.4%) despite similar doses of FSH/hMG (3,627 vs. 3,804 IU). Adding 2.5 mg of letrozole to a high-dose FSH/hMG antagonist protocol increases intraovarian androstenedione and T concentration and improves IVF cycle outcome in poor responder patients." @default.
- W2022889910 created "2016-06-24" @default.
- W2022889910 creator A5010495170 @default.
- W2022889910 creator A5027057730 @default.
- W2022889910 creator A5041103241 @default.
- W2022889910 creator A5054849352 @default.
- W2022889910 creator A5057833828 @default.
- W2022889910 creator A5058167634 @default.
- W2022889910 creator A5080703733 @default.
- W2022889910 date "2005-07-01" @default.
- W2022889910 modified "2023-10-07" @default.
- W2022889910 title "The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: A pilot study" @default.
- W2022889910 cites W1959072027 @default.
- W2022889910 cites W1963606316 @default.
- W2022889910 cites W1970196453 @default.
- W2022889910 cites W1974588053 @default.
- W2022889910 cites W1974835134 @default.
- W2022889910 cites W1982055210 @default.
- W2022889910 cites W1993816409 @default.
- W2022889910 cites W1994089867 @default.
- W2022889910 cites W1995790468 @default.
- W2022889910 cites W2014686801 @default.
- W2022889910 cites W2015159617 @default.
- W2022889910 cites W2015325021 @default.
- W2022889910 cites W2023963334 @default.
- W2022889910 cites W2028967585 @default.
- W2022889910 cites W2036372570 @default.
- W2022889910 cites W2096422392 @default.
- W2022889910 cites W2101045687 @default.
- W2022889910 cites W2104333780 @default.
- W2022889910 cites W2114124243 @default.
- W2022889910 cites W2123258613 @default.
- W2022889910 cites W2141822192 @default.
- W2022889910 cites W2148151452 @default.
- W2022889910 cites W2149121013 @default.
- W2022889910 cites W2161330749 @default.
- W2022889910 cites W2163137316 @default.
- W2022889910 cites W2164589616 @default.
- W2022889910 cites W2168163621 @default.
- W2022889910 cites W2170309753 @default.
- W2022889910 cites W2172258960 @default.
- W2022889910 cites W2207167603 @default.
- W2022889910 cites W2262309978 @default.
- W2022889910 cites W2401840272 @default.
- W2022889910 cites W2412136201 @default.
- W2022889910 cites W4236627566 @default.
- W2022889910 doi "https://doi.org/10.1016/j.fertnstert.2005.01.117" @default.
- W2022889910 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16009161" @default.
- W2022889910 hasPublicationYear "2005" @default.
- W2022889910 type Work @default.
- W2022889910 sameAs 2022889910 @default.
- W2022889910 citedByCount "216" @default.
- W2022889910 countsByYear W20228899102012 @default.
- W2022889910 countsByYear W20228899102013 @default.
- W2022889910 countsByYear W20228899102014 @default.
- W2022889910 countsByYear W20228899102015 @default.
- W2022889910 countsByYear W20228899102016 @default.
- W2022889910 countsByYear W20228899102017 @default.
- W2022889910 countsByYear W20228899102018 @default.
- W2022889910 countsByYear W20228899102019 @default.
- W2022889910 countsByYear W20228899102020 @default.
- W2022889910 countsByYear W20228899102021 @default.
- W2022889910 countsByYear W20228899102022 @default.
- W2022889910 countsByYear W20228899102023 @default.
- W2022889910 crossrefType "journal-article" @default.
- W2022889910 hasAuthorship W2022889910A5010495170 @default.
- W2022889910 hasAuthorship W2022889910A5027057730 @default.
- W2022889910 hasAuthorship W2022889910A5041103241 @default.
- W2022889910 hasAuthorship W2022889910A5054849352 @default.
- W2022889910 hasAuthorship W2022889910A5057833828 @default.
- W2022889910 hasAuthorship W2022889910A5058167634 @default.
- W2022889910 hasAuthorship W2022889910A5080703733 @default.
- W2022889910 hasBestOaLocation W20228899101 @default.
- W2022889910 hasConcept C121608353 @default.
- W2022889910 hasConcept C126322002 @default.
- W2022889910 hasConcept C134018914 @default.
- W2022889910 hasConcept C16685009 @default.
- W2022889910 hasConcept C187785154 @default.
- W2022889910 hasConcept C2776166826 @default.
- W2022889910 hasConcept C2776537878 @default.
- W2022889910 hasConcept C2776683971 @default.
- W2022889910 hasConcept C2777911890 @default.
- W2022889910 hasConcept C2778504769 @default.
- W2022889910 hasConcept C2778812593 @default.
- W2022889910 hasConcept C2779234561 @default.
- W2022889910 hasConcept C2779279991 @default.
- W2022889910 hasConcept C512716672 @default.
- W2022889910 hasConcept C530470458 @default.
- W2022889910 hasConcept C54355233 @default.
- W2022889910 hasConcept C71315377 @default.
- W2022889910 hasConcept C71924100 @default.
- W2022889910 hasConcept C86803240 @default.
- W2022889910 hasConceptScore W2022889910C121608353 @default.
- W2022889910 hasConceptScore W2022889910C126322002 @default.
- W2022889910 hasConceptScore W2022889910C134018914 @default.
- W2022889910 hasConceptScore W2022889910C16685009 @default.
- W2022889910 hasConceptScore W2022889910C187785154 @default.
- W2022889910 hasConceptScore W2022889910C2776166826 @default.